annual total liabilities:
$124.90B-$12.31B(-8.97%)Summary
- As of today (April 12, 2025), PFE annual total liabilities is $124.90 billion, with the most recent change of -$12.31 billion (-8.97%) on December 1, 2024.
- During the last 3 years, PFE annual total liabilities has risen by +$20.89 billion (+20.08%).
- PFE annual total liabilities is now -8.97% below its all-time high of $137.21 billion, reached on December 31, 2023.
Performance
PFE Total liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly total liabilities:
$124.90B-$2.02B(-1.59%)Summary
- As of today (April 12, 2025), PFE quarterly total liabilities is $124.90 billion, with the most recent change of -$2.02 billion (-1.59%) on December 1, 2024.
- Over the past year, PFE quarterly total liabilities has stayed the same.
- PFE quarterly total liabilities is now -8.97% below its all-time high of $137.21 billion, reached on December 31, 2023.
Performance
PFE quarterly total liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Total liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
PFE Total liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -9.0% | 0.0% |
| 3 y3 years | +20.1% | 0.0% |
| 5 y5 years | +19.9% | 0.0% |
PFE Total liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -9.0% | +23.3% | -9.0% | +32.3% |
| 5 y | 5-year | -9.0% | +37.6% | -9.0% | +38.9% |
| alltime | all time | -9.0% | +8033.6% | -9.0% | +8033.6% |
Pfizer Total liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $124.90B(-9.0%) | $124.90B(-1.6%) |
| Sep 2024 | - | $126.92B(-1.0%) |
| Jun 2024 | - | $128.22B(-0.2%) |
| Mar 2024 | - | $128.54B(-6.3%) |
| Dec 2023 | $137.21B(+35.5%) | $137.21B(+16.5%) |
| Sep 2023 | - | $117.82B(-2.5%) |
| Jun 2023 | - | $120.88B(+28.1%) |
| Mar 2023 | - | $94.38B(-6.8%) |
| Dec 2022 | $101.29B(-2.6%) | $101.29B(-1.1%) |
| Sep 2022 | - | $102.46B(-5.0%) |
| Jun 2022 | - | $107.82B(+6.6%) |
| Mar 2022 | - | $101.16B(-2.7%) |
| Dec 2021 | $104.01B(+14.6%) | $104.01B(+0.8%) |
| Sep 2021 | - | $103.22B(+3.6%) |
| Jun 2021 | - | $99.61B(+10.7%) |
| Mar 2021 | - | $89.95B(-0.9%) |
| Dec 2020 | $90.76B(-12.9%) | $90.76B(-20.0%) |
| Sep 2020 | - | $113.49B(+0.1%) |
| Jun 2020 | - | $113.37B(+12.2%) |
| Mar 2020 | - | $101.00B(-3.0%) |
| Dec 2019 | $104.15B(+8.9%) | $104.15B(-0.9%) |
| Sep 2019 | - | $105.05B(+9.1%) |
| Jun 2019 | - | $96.28B(+0.0%) |
| Mar 2019 | - | $96.26B(+0.6%) |
| Dec 2018 | $95.66B(-4.5%) | $95.66B(-0.5%) |
| Sep 2018 | - | $96.17B(+1.4%) |
| Jun 2018 | - | $94.86B(+0.8%) |
| Mar 2018 | - | $94.07B(-6.1%) |
| Dec 2017 | $100.14B(-10.4%) | $100.14B(-9.8%) |
| Sep 2017 | - | $111.04B(+1.1%) |
| Jun 2017 | - | $109.86B(-0.2%) |
| Mar 2017 | - | $110.04B(-1.6%) |
| Dec 2016 | $111.78B(+9.2%) | $111.78B(-2.7%) |
| Sep 2016 | - | $114.83B(+6.7%) |
| Jun 2016 | - | $107.59B(+8.0%) |
| Mar 2016 | - | $99.58B(-2.7%) |
| Dec 2015 | $102.38B(+6.7%) | $102.38B(-1.3%) |
| Sep 2015 | - | $103.74B(+10.7%) |
| Jun 2015 | - | $93.70B(+0.7%) |
| Mar 2015 | - | $93.05B(-3.0%) |
| Dec 2014 | $95.94B(+0.5%) | $95.94B(+3.1%) |
| Sep 2014 | - | $93.06B(-2.7%) |
| Jun 2014 | - | $95.66B(+2.0%) |
| Mar 2014 | - | $93.74B(-1.8%) |
| Dec 2013 | $95.48B(-8.3%) | $95.48B(-1.7%) |
| Sep 2013 | - | $97.17B(-3.2%) |
| Jun 2013 | - | $100.36B(-4.0%) |
| Mar 2013 | - | $104.57B(+0.4%) |
| Dec 2012 | $104.12B(-1.2%) | $104.12B(+3.6%) |
| Sep 2012 | - | $100.49B(-2.3%) |
| Jun 2012 | - | $102.88B(+0.9%) |
| Mar 2012 | - | $102.01B(-3.2%) |
| Dec 2011 | $105.38B(-1.3%) | $105.38B(-0.2%) |
| Sep 2011 | - | $105.60B(-1.2%) |
| Jun 2011 | - | $106.94B(+2.4%) |
| Mar 2011 | - | $104.42B(-2.2%) |
| Dec 2010 | $106.75B(-12.9%) | $106.75B(+3.3%) |
| Sep 2010 | - | $103.35B(-0.8%) |
| Jun 2010 | - | $104.19B(-0.8%) |
| Mar 2010 | - | $105.03B(-14.3%) |
| Dec 2009 | $122.50B(+129.4%) | $122.50B(+63.2%) |
| Sep 2009 | - | $75.04B(-1.4%) |
| Jun 2009 | - | $76.10B(+21.8%) |
| Mar 2009 | - | $62.49B(+17.0%) |
| Dec 2008 | $53.41B(+6.5%) | $53.41B(+11.8%) |
| Sep 2008 | - | $47.76B(-4.1%) |
| Jun 2008 | - | $49.80B(-2.3%) |
| Mar 2008 | - | $50.99B(+1.7%) |
| Dec 2007 | $50.14B(+13.7%) | $50.14B(+18.2%) |
| Sep 2007 | - | $42.42B(+0.3%) |
| Jun 2007 | - | $42.31B(+11.4%) |
| Mar 2007 | - | $37.99B(-13.9%) |
| Dec 2006 | $44.11B | $44.11B(+13.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2006 | - | $38.87B(-9.7%) |
| Jun 2006 | - | $43.06B(-0.7%) |
| Mar 2006 | - | $43.35B(-15.3%) |
| Dec 2005 | $51.21B(-6.6%) | $51.21B(+17.6%) |
| Sep 2005 | - | $43.54B(-7.4%) |
| Jun 2005 | - | $47.00B(-15.2%) |
| Mar 2005 | - | $55.40B(+1.1%) |
| Dec 2004 | $54.80B(+6.6%) | $54.80B(+1.8%) |
| Sep 2004 | - | $53.85B(+1.1%) |
| Jun 2004 | - | $53.26B(+0.0%) |
| Mar 2004 | - | $53.24B(+3.6%) |
| Dec 2003 | $51.40B(+94.6%) | $51.40B(-0.3%) |
| Sep 2003 | - | $51.53B(-4.5%) |
| Jun 2003 | - | $53.98B(+92.2%) |
| Mar 2003 | - | $28.09B(+6.4%) |
| Dec 2002 | $26.41B(+26.6%) | $26.41B(+1.9%) |
| Sep 2002 | - | $25.92B(+9.2%) |
| Jun 2002 | - | $23.74B(+9.7%) |
| Mar 2002 | - | $21.64B(+3.7%) |
| Dec 2001 | $20.86B(+19.7%) | $20.86B(+4.8%) |
| Sep 2001 | - | $19.91B(+4.1%) |
| Jun 2001 | - | $19.13B(+9.9%) |
| Mar 2001 | - | $17.40B(-0.2%) |
| Dec 2000 | $17.43B(+0.1%) | $17.43B(+0.7%) |
| Sep 2000 | - | $17.32B(+1.4%) |
| Jun 2000 | - | $17.07B(+70.1%) |
| Mar 2000 | - | $10.04B(-42.4%) |
| Dec 1999 | $17.42B(+83.5%) | $17.42B(+52.1%) |
| Sep 1999 | - | $11.45B(+4.2%) |
| Jun 1999 | - | $10.99B(+10.1%) |
| Mar 1999 | - | $9.98B(+5.1%) |
| Dec 1998 | $9.49B(+34.5%) | $9.49B(-0.4%) |
| Sep 1998 | - | $9.53B(+16.2%) |
| Jun 1998 | - | $8.20B(+5.6%) |
| Mar 1998 | - | $7.77B(+10.0%) |
| Dec 1997 | $7.06B(-7.9%) | $7.06B(-10.7%) |
| Sep 1997 | - | $7.90B(-7.3%) |
| Jun 1997 | - | $8.52B(+8.4%) |
| Mar 1997 | - | $7.86B(+2.6%) |
| Dec 1996 | $7.66B(+6.8%) | $7.66B(-4.2%) |
| Sep 1996 | - | $8.00B(+5.4%) |
| Jun 1996 | - | $7.59B(+4.8%) |
| Mar 1996 | - | $7.24B(+0.9%) |
| Dec 1995 | $7.18B(+6.5%) | $7.18B(-4.2%) |
| Sep 1995 | - | $7.49B(-7.2%) |
| Jun 1995 | - | $8.07B(+3.8%) |
| Mar 1995 | - | $7.78B(+15.5%) |
| Dec 1994 | $6.74B(+24.1%) | $6.74B(+8.5%) |
| Sep 1994 | - | $6.21B(-1.7%) |
| Jun 1994 | - | $6.32B(+9.5%) |
| Mar 1994 | - | $5.77B(+6.3%) |
| Dec 1993 | $5.43B(+12.2%) | $5.43B(-9.9%) |
| Sep 1993 | - | $6.02B(+4.2%) |
| Jun 1993 | - | $5.78B(+10.3%) |
| Mar 1993 | - | $5.24B(+8.3%) |
| Dec 1992 | $4.84B(+5.7%) | $4.84B(+4.5%) |
| Sep 1992 | - | $4.63B(+3.1%) |
| Jun 1992 | - | $4.49B(+2.7%) |
| Mar 1992 | - | $4.37B(-4.5%) |
| Dec 1991 | $4.57B(+16.3%) | $4.57B(+17.1%) |
| Sep 1991 | - | $3.91B(-1.5%) |
| Jun 1991 | - | $3.97B(+10.0%) |
| Mar 1991 | - | $3.61B(-8.3%) |
| Dec 1990 | $3.93B(+4.4%) | $3.93B(+12.7%) |
| Sep 1990 | - | $3.49B(+2.7%) |
| Jun 1990 | - | $3.39B(+6.4%) |
| Mar 1990 | - | $3.19B(-15.3%) |
| Dec 1989 | $3.76B(+12.8%) | $3.76B(+12.8%) |
| Dec 1988 | $3.34B(+9.7%) | $3.34B(+9.7%) |
| Dec 1987 | $3.04B(+73.9%) | $3.04B(+73.9%) |
| Dec 1986 | $1.75B(+13.9%) | $1.75B(+13.9%) |
| Dec 1985 | $1.54B(-1.7%) | $1.54B(-1.7%) |
| Dec 1984 | $1.56B | $1.56B |
FAQ
- What is Pfizer annual total liabilities?
- What is the all time high annual total liabilities for Pfizer?
- What is Pfizer annual total liabilities year-on-year change?
- What is Pfizer quarterly total liabilities?
- What is the all time high quarterly total liabilities for Pfizer?
- What is Pfizer quarterly total liabilities year-on-year change?
What is Pfizer annual total liabilities?
The current annual total liabilities of PFE is $124.90B
What is the all time high annual total liabilities for Pfizer?
Pfizer all-time high annual total liabilities is $137.21B
What is Pfizer annual total liabilities year-on-year change?
Over the past year, PFE annual total liabilities has changed by -$12.31B (-8.97%)
What is Pfizer quarterly total liabilities?
The current quarterly total liabilities of PFE is $124.90B
What is the all time high quarterly total liabilities for Pfizer?
Pfizer all-time high quarterly total liabilities is $137.21B
What is Pfizer quarterly total liabilities year-on-year change?
Over the past year, PFE quarterly total liabilities has changed by $0.00 (0.00%)